Global Molecular Diagnostics Market: Focus on Product Type (Kits and Consumables, Systems, Software & Others), Applications, Technologies, End-User, Country Data (15 Countries), and Competitive Landscape: Analysis and Forecast: 2018-2028
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
Since the dawn of the precision medicine era, the entire gamut of the healthcare industry has witnessed a paradigm change toward more precise diagnostics. The increasing prevalence of chronic disorders and an overall increased demand for preventive medication with minimal/no side-effect are promoting the growth of the global molecular diagnostics market, providing platform for the designing and development of highly enhanced and optimum products that would direct patients to their appropriate treatment modules. These individualized care regimes are improving the quality of life of the patients and reducing economic, societal, and clinical burden, projecting a future of prosperity.
Presently, product categories within the molecular diagnostics market include kits and consumables, systems, and software and others. Till date, the healthcare industry has witnessed a number of successful products that have contributed significantly in enhancing the technological advancements in making molecular diagnostics more precise. However, the consistent evolution of the market has further necessitated the insurgence of more advanced research initiatives that look to devise the optimum assay with the confluence of multiplexing and low cost. Additionally, with systems being developed at the interface of different technologies, precision diagnostics is soon to become a widespread reality.
The purpose of the study is to gain a holistic view of the global molecular diagnostics market in terms of various factors, including regulatory reforms and technological advancements, which are influencing the market. The market has been segmented into ‘products’, ‘applications’, ‘technologies’, ‘end-users’, and ‘regions’. The scope of this report is centered upon conducting a detailed study of the products allied with the molecular diagnostics market. In addition, the study also includes the exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each product, application, technology, end-user, region, and companies, as well as other vital information with respect to molecular diagnostics market. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.
This research report aims at answering various aspects of the global molecular diagnostics market with the help of the key factors driving the market, the restraints, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.
The research study highlights the factors governing the industry attractiveness with Porter’s Five Forces for a comprehensive understanding of the global molecular diagnostics market. Moreover, the study includes detailed product mapping, market estimation, and analysis of key trends in multiple geographical regions, growth of molecular diagnostics market in each region for different applications, and the key strategies and developments by the prominent molecular diagnostics manufacturers.
The answers to the following key questions can be derived from this report:
Since the dawn of the precision medicine era, the entire gamut of the healthcare industry has witnessed a paradigm change toward more precise diagnostics. The increasing prevalence of chronic disorders and an overall increased demand for preventive medication with minimal/no side-effect are promoting the growth of the global molecular diagnostics market, providing platform for the designing and development of highly enhanced and optimum products that would direct patients to their appropriate treatment modules. These individualized care regimes are improving the quality of life of the patients and reducing economic, societal, and clinical burden, projecting a future of prosperity.
Presently, product categories within the molecular diagnostics market include kits and consumables, systems, and software and others. Till date, the healthcare industry has witnessed a number of successful products that have contributed significantly in enhancing the technological advancements in making molecular diagnostics more precise. However, the consistent evolution of the market has further necessitated the insurgence of more advanced research initiatives that look to devise the optimum assay with the confluence of multiplexing and low cost. Additionally, with systems being developed at the interface of different technologies, precision diagnostics is soon to become a widespread reality.
The purpose of the study is to gain a holistic view of the global molecular diagnostics market in terms of various factors, including regulatory reforms and technological advancements, which are influencing the market. The market has been segmented into ‘products’, ‘applications’, ‘technologies’, ‘end-users’, and ‘regions’. The scope of this report is centered upon conducting a detailed study of the products allied with the molecular diagnostics market. In addition, the study also includes the exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each product, application, technology, end-user, region, and companies, as well as other vital information with respect to molecular diagnostics market. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.
This research report aims at answering various aspects of the global molecular diagnostics market with the help of the key factors driving the market, the restraints, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.
The research study highlights the factors governing the industry attractiveness with Porter’s Five Forces for a comprehensive understanding of the global molecular diagnostics market. Moreover, the study includes detailed product mapping, market estimation, and analysis of key trends in multiple geographical regions, growth of molecular diagnostics market in each region for different applications, and the key strategies and developments by the prominent molecular diagnostics manufacturers.
The answers to the following key questions can be derived from this report:
- What are the major market drivers, challenges, and opportunities in the global molecular diagnostics market?
- What are the underlying structures resulting in the emerging trends within the global molecular diagnostics market?
- How will each segment of the global molecular diagnostics market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2028?
- What are the key developmental strategies which are implemented by the major players in order to sustain in the competitive market? What are the key regulatory implications in developed and developing regions for molecular diagnostics?
- Who are the leading players with significant offerings to the global molecular diagnostics market? What is the current market dominance for each of these leading players?
- What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2018-2028? Which molecular diagnostic product type is having the most promising growth?
- What are the key applications in global molecular diagnostics market? What are the major segments of these applications? What technologies are dominating these application segments?
- What are the major technologies that are employed in the global molecular diagnostics market? Which is the dominating technology?
- Who are the primary end-users of the global molecular diagnostics market? Which is the fastest growing end-use segment in the global molecular diagnostics market?
- Who are the key manufacturers in the global molecular diagnostics market, and what are their contributions? Also, what is the growth potential of each major molecular diagnostics manufacturer?
- What is the scope of the global molecular diagnostics market in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World? Which molecular diagnostics application dominates these regions?
- What are the emerging trends in the global molecular diagnostics market? How are these trends revolutionizing the diagnostic procedure?
- Which technologies are anticipated to break-through the current molecular diagnostic regime?
- Which companies are anticipated to be highly disruptive in the future and why?
- What are the regulatory procedures that are required to unify the approval process for emerging molecular diagnostics? How will they enhance the reimbursement scenario?
- What are the gaps in regularizing optimum molecular diagnostic adoption in regular healthcare routines? How are these gaps being tackled?
1 MARKET OVERVIEW
1.1 Introduction
1.2 Market Definition
1.3 Historical Perspective
1.4 Significant Technologies
1.5 Classification of Molecular Diagnostics
1.6 Global Footprint
1.7 Future Potential
2 MARKET DYNAMICS
2.1 Overview
2.2 Iceberg Analysis - Global Molecular Diagnostics Market
2.3 Impact Analysis
2.4 Market Drivers
2.4.1 A Highly Increasing Prevalence of Infectious Diseases and Various Types of Cancer, Globally
2.4.2 Growth in the Biomarker Identification Market and Advancements in Molecular Techniques
2.4.3 Increase in Awareness and Acceptance of Personalized Medicines on a Global Level
2.4.4 Significant External Funding for Executing Research and Development Exercises
2.5 Market Restraints
2.5.1 Uncertain Reimbursement Scenario
2.5.2 Lack of High-Complexity Testing Centers
2.5.3 Complex Regulatory Frameworks Delaying the Approval of New Molecular Diagnostic Tests
2.6 Market Opportunities
2.6.1 Massive Scope for Adoption of Molecular Diagnostics in Emerging Nations
2.6.2 Increase in the Adoption of Automation & Multiplexing of Technologies
2.6.3 Rise of Next Generation Ultrasensitive Molecular Diagnostics
2.6.4 Novel Revenue Streams
3 COMPETITIVE LANDSCAPE
3.1 Key Strategies and Developments
3.1.1 Synergistic Activities
3.1.2 Approvals
3.1.3 Product Launches and Enhancements
3.1.4 Acquisitions
3.1.5 Funding and Expansion Activities
3.2 Market Share Analysis
3.3 Growth Share Analysis (Opportunity Mapping)
3.4 Industry Attractiveness
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Threat of New Entrants
3.4.4 Threat of Substitute Products
3.4.5 Intensity of Competitive Rivalry
4 REGULATORY FRAMEWORK
4.1 Legal Requirements and Framework in the U.S.
4.2 Legal Requirements and Framework in Europe
4.3 Legal Requirements and Framework in Asia-Pacific
4.3.1 China
4.3.2 Japan
5 GLOBAL MOLECULAR DIAGNOSTICS MARKET (BY PRODUCT)
5.1 Overview
5.2 Kits and Consumables
5.3 Systems
5.4 Software and Other Products
6 GLOBAL MOLECULAR DIAGNOSTICS MARKET (BY APPLICATION)
6.1 Overview
6.2 Core Molecular Diagnostics
6.2.1 Infectious Diseases
6.2.2 Genetic Testing
6.2.3 Blood Donor Screening
6.2.4 Oncology (Excluding Companion Diagnostics and Liquid Biopsy)
6.2.5 Human Leukocyte Antigen (HLA) Testing
6.2.6 Other Applications
6.3 Non-Invasive Prenatal Testing (NIPT)
6.4 Companion Diagnostics
6.5 Liquid Biopsy
7 GLOBAL MOLECULAR DIAGNOSTICS MARKET (BY TECHNOLOGY)
7.1 Overview
7.2 Polymerase Chain Reaction (PCR)
7.3 Sequencing
7.4 Microarray
7.5 In-situ Hybridization
7.6 Immunohistochemistry
7.7 Nucleic Acid Amplification
7.8 Isothermal Amplification
7.9 Others
8 GLOBAL MOLECULAR DIAGNOSTICS MARKET (BY END-USER)
8.1 Overview
8.2 Hospitals
8.3 Diagnostic Centers
8.4 Out-Patient Clinics/General Practitioners
8.5 Research Laboratories
9 GLOBAL MOLECULAR DIAGNOSTICS MARKET (BY REGION)
9.1 Overview
9.2 North America
9.2.1 The U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 France
9.3.3 Italy
9.3.4 The U.K.
9.3.5 Spain
9.3.6 The Netherlands
9.3.7 Rest-of-Europe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Singapore
9.4.6 Rest-of-APAC
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest-of-Latin America
9.6 Rest-of-the-World
10 COMPANY PROFILES
10.1 Overview
10.2 Abbott Laboratories
10.2.1 Company Overview
10.2.2 Role of Abbott Laboratories in the Molecular Diagnostics Market
10.2.3 Financials
10.2.4 Key Insights about Financial Health of the Company
10.2.5 SWOT Analysis
10.3 Agilent Technologies, Inc.
10.3.1 Company Overview
10.3.2 Role of Agilent Technologies, Inc. in the Molecular Diagnostics Market
10.3.3 Financials
10.3.4 Key Insights about Financial Health of the Company
10.3.5 SWOT Analysis
10.4 Becton, Dickinson and Company
10.4.1 Company Overview
10.4.2 Role of Becton, Dickinson and Company in the Molecular Diagnostics Market
10.4.3 Financials
10.4.4 Key Insights about Financial Health of the Company
10.4.5 SWOT Analysis
10.5 bioMйrieux S.A.
10.5.1 Company Overview
10.5.2 Role of bioMйrieux S.A. in the Molecular Diagnostics Market
10.5.3 Financials
10.5.4 Key Insights about Financial Health of the Company
10.5.5 SWOT Analysis
10.6 Bio-Rad Laboratories, Inc.
10.6.1 Company Overview
10.6.2 Role of Bio-Rad Laboratories, Inc. in the Molecular Diagnostics Market
10.6.3 Financials
10.6.4 Key Insights about Financial Health of the Company
10.6.5 SWOT Analysis
10.7 Cynvenio Biosystems, Inc.
10.7.1 Company Overview
10.7.2 Role of Cynvenio Biosystems, Inc. in the Molecular Diagnostics Market
10.7.3 SWOT Analysis
10.8 Danaher Corporation
10.8.1 Company Overview
10.8.2 Role of Danaher Corporation in the Molecular Diagnostics Market
10.8.3 Financials
10.8.4 Key Insights about Financial Health of the Company
10.8.5 SWOT Analysis
10.9 F. Hoffmann-La Roche AG
10.9.1 Company Overview
10.9.2 Role of F. Hoffmann-La Roche AG in the Molecular Diagnostics Market
10.9.3 Financials
10.9.4 Key Insights about Financial Health of the Company
10.9.5 SWOT Analysis
10.10 GUARDANT HEALTH, INC
10.10.1 Company Overview
10.10.2 Role of GUARDANT HEALTH, INC in the Molecular Diagnostics Market
10.10.3 SWOT Analysis
10.11 Illumina, Inc.
10.11.1 Company Overview
10.11.2 Role of Illumina, Inc. in the Molecular Diagnostics Market
10.11.3 Financials
10.11.4 Key Insights about Financial Health of the Company
10.11.5 SWOT Analysis
10.12 Invivoscribe Technologies, Inc.
10.12.1 Company Overview
10.12.2 Role of Invivoscribe Technologies, Inc. in the Molecular Diagnostics Market
10.12.3 SWOT Analysis
10.13 MolecularMD Corporation
10.13.1 Company Overview
10.13.2 Role of MolecularMD Corporation in the Molecular Diagnostics Market
10.13.3 SWOT Analysis
10.14 QIAGEN N.V.
10.14.1 Company Overview
10.14.2 Role of QIAGEN N.V. in the Molecular Diagnostics Market
10.14.3 Financials
10.14.4 Key Insights about Financial Health of the Company
10.14.5 SWOT Analysis
10.15 Siemens Healthineers, Inc.
10.15.1 Company Overview
10.15.2 Role of Siemens Healthineers, Inc. in the Molecular Diagnostics Market
10.15.3 Financials
10.15.4 Key Insights about Financial Health of the Company
10.15.5 SWOT Analysis
10.16 Thermo Fisher Scientific Inc.
10.16.1 Company Overview
10.16.2 Role of Thermo Fisher Scientific Inc. in the Molecular Diagnostics Market
10.16.3 Financials
10.16.4 Key Insights about Financial Health of the Company
10.16.5 SWOT Analysis
10.17 QuantuMDx Group Ltd.
10.17.1 Company Overview
10.17.2 Role of QuantuMDx Group Ltd. in the Molecular Diagnostics Market
10.18 HTG Molecular Diagnostics, Inc.
10.18.1 Company Overview
10.18.2 Role of HTG Molecular Diagnostics, Inc. in the Molecular Diagnostics Market
11 RESEARCH SCOPE AND METHODOLOGY
11.1 Report Scope
11.2 Global Molecular Diagnostics Market: Research Methodology
1.1 Introduction
1.2 Market Definition
1.3 Historical Perspective
1.4 Significant Technologies
1.5 Classification of Molecular Diagnostics
1.6 Global Footprint
1.7 Future Potential
2 MARKET DYNAMICS
2.1 Overview
2.2 Iceberg Analysis - Global Molecular Diagnostics Market
2.3 Impact Analysis
2.4 Market Drivers
2.4.1 A Highly Increasing Prevalence of Infectious Diseases and Various Types of Cancer, Globally
2.4.2 Growth in the Biomarker Identification Market and Advancements in Molecular Techniques
2.4.3 Increase in Awareness and Acceptance of Personalized Medicines on a Global Level
2.4.4 Significant External Funding for Executing Research and Development Exercises
2.5 Market Restraints
2.5.1 Uncertain Reimbursement Scenario
2.5.2 Lack of High-Complexity Testing Centers
2.5.3 Complex Regulatory Frameworks Delaying the Approval of New Molecular Diagnostic Tests
2.6 Market Opportunities
2.6.1 Massive Scope for Adoption of Molecular Diagnostics in Emerging Nations
2.6.2 Increase in the Adoption of Automation & Multiplexing of Technologies
2.6.3 Rise of Next Generation Ultrasensitive Molecular Diagnostics
2.6.4 Novel Revenue Streams
3 COMPETITIVE LANDSCAPE
3.1 Key Strategies and Developments
3.1.1 Synergistic Activities
3.1.2 Approvals
3.1.3 Product Launches and Enhancements
3.1.4 Acquisitions
3.1.5 Funding and Expansion Activities
3.2 Market Share Analysis
3.3 Growth Share Analysis (Opportunity Mapping)
3.4 Industry Attractiveness
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Threat of New Entrants
3.4.4 Threat of Substitute Products
3.4.5 Intensity of Competitive Rivalry
4 REGULATORY FRAMEWORK
4.1 Legal Requirements and Framework in the U.S.
4.2 Legal Requirements and Framework in Europe
4.3 Legal Requirements and Framework in Asia-Pacific
4.3.1 China
4.3.2 Japan
5 GLOBAL MOLECULAR DIAGNOSTICS MARKET (BY PRODUCT)
5.1 Overview
5.2 Kits and Consumables
5.3 Systems
5.4 Software and Other Products
6 GLOBAL MOLECULAR DIAGNOSTICS MARKET (BY APPLICATION)
6.1 Overview
6.2 Core Molecular Diagnostics
6.2.1 Infectious Diseases
6.2.2 Genetic Testing
6.2.3 Blood Donor Screening
6.2.4 Oncology (Excluding Companion Diagnostics and Liquid Biopsy)
6.2.5 Human Leukocyte Antigen (HLA) Testing
6.2.6 Other Applications
6.3 Non-Invasive Prenatal Testing (NIPT)
6.4 Companion Diagnostics
6.5 Liquid Biopsy
7 GLOBAL MOLECULAR DIAGNOSTICS MARKET (BY TECHNOLOGY)
7.1 Overview
7.2 Polymerase Chain Reaction (PCR)
7.3 Sequencing
7.4 Microarray
7.5 In-situ Hybridization
7.6 Immunohistochemistry
7.7 Nucleic Acid Amplification
7.8 Isothermal Amplification
7.9 Others
8 GLOBAL MOLECULAR DIAGNOSTICS MARKET (BY END-USER)
8.1 Overview
8.2 Hospitals
8.3 Diagnostic Centers
8.4 Out-Patient Clinics/General Practitioners
8.5 Research Laboratories
9 GLOBAL MOLECULAR DIAGNOSTICS MARKET (BY REGION)
9.1 Overview
9.2 North America
9.2.1 The U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 France
9.3.3 Italy
9.3.4 The U.K.
9.3.5 Spain
9.3.6 The Netherlands
9.3.7 Rest-of-Europe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Singapore
9.4.6 Rest-of-APAC
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest-of-Latin America
9.6 Rest-of-the-World
10 COMPANY PROFILES
10.1 Overview
10.2 Abbott Laboratories
10.2.1 Company Overview
10.2.2 Role of Abbott Laboratories in the Molecular Diagnostics Market
10.2.3 Financials
10.2.4 Key Insights about Financial Health of the Company
10.2.5 SWOT Analysis
10.3 Agilent Technologies, Inc.
10.3.1 Company Overview
10.3.2 Role of Agilent Technologies, Inc. in the Molecular Diagnostics Market
10.3.3 Financials
10.3.4 Key Insights about Financial Health of the Company
10.3.5 SWOT Analysis
10.4 Becton, Dickinson and Company
10.4.1 Company Overview
10.4.2 Role of Becton, Dickinson and Company in the Molecular Diagnostics Market
10.4.3 Financials
10.4.4 Key Insights about Financial Health of the Company
10.4.5 SWOT Analysis
10.5 bioMйrieux S.A.
10.5.1 Company Overview
10.5.2 Role of bioMйrieux S.A. in the Molecular Diagnostics Market
10.5.3 Financials
10.5.4 Key Insights about Financial Health of the Company
10.5.5 SWOT Analysis
10.6 Bio-Rad Laboratories, Inc.
10.6.1 Company Overview
10.6.2 Role of Bio-Rad Laboratories, Inc. in the Molecular Diagnostics Market
10.6.3 Financials
10.6.4 Key Insights about Financial Health of the Company
10.6.5 SWOT Analysis
10.7 Cynvenio Biosystems, Inc.
10.7.1 Company Overview
10.7.2 Role of Cynvenio Biosystems, Inc. in the Molecular Diagnostics Market
10.7.3 SWOT Analysis
10.8 Danaher Corporation
10.8.1 Company Overview
10.8.2 Role of Danaher Corporation in the Molecular Diagnostics Market
10.8.3 Financials
10.8.4 Key Insights about Financial Health of the Company
10.8.5 SWOT Analysis
10.9 F. Hoffmann-La Roche AG
10.9.1 Company Overview
10.9.2 Role of F. Hoffmann-La Roche AG in the Molecular Diagnostics Market
10.9.3 Financials
10.9.4 Key Insights about Financial Health of the Company
10.9.5 SWOT Analysis
10.10 GUARDANT HEALTH, INC
10.10.1 Company Overview
10.10.2 Role of GUARDANT HEALTH, INC in the Molecular Diagnostics Market
10.10.3 SWOT Analysis
10.11 Illumina, Inc.
10.11.1 Company Overview
10.11.2 Role of Illumina, Inc. in the Molecular Diagnostics Market
10.11.3 Financials
10.11.4 Key Insights about Financial Health of the Company
10.11.5 SWOT Analysis
10.12 Invivoscribe Technologies, Inc.
10.12.1 Company Overview
10.12.2 Role of Invivoscribe Technologies, Inc. in the Molecular Diagnostics Market
10.12.3 SWOT Analysis
10.13 MolecularMD Corporation
10.13.1 Company Overview
10.13.2 Role of MolecularMD Corporation in the Molecular Diagnostics Market
10.13.3 SWOT Analysis
10.14 QIAGEN N.V.
10.14.1 Company Overview
10.14.2 Role of QIAGEN N.V. in the Molecular Diagnostics Market
10.14.3 Financials
10.14.4 Key Insights about Financial Health of the Company
10.14.5 SWOT Analysis
10.15 Siemens Healthineers, Inc.
10.15.1 Company Overview
10.15.2 Role of Siemens Healthineers, Inc. in the Molecular Diagnostics Market
10.15.3 Financials
10.15.4 Key Insights about Financial Health of the Company
10.15.5 SWOT Analysis
10.16 Thermo Fisher Scientific Inc.
10.16.1 Company Overview
10.16.2 Role of Thermo Fisher Scientific Inc. in the Molecular Diagnostics Market
10.16.3 Financials
10.16.4 Key Insights about Financial Health of the Company
10.16.5 SWOT Analysis
10.17 QuantuMDx Group Ltd.
10.17.1 Company Overview
10.17.2 Role of QuantuMDx Group Ltd. in the Molecular Diagnostics Market
10.18 HTG Molecular Diagnostics, Inc.
10.18.1 Company Overview
10.18.2 Role of HTG Molecular Diagnostics, Inc. in the Molecular Diagnostics Market
11 RESEARCH SCOPE AND METHODOLOGY
11.1 Report Scope
11.2 Global Molecular Diagnostics Market: Research Methodology
LIST OF TABLES
Table 2.1: Impact Analysis of Market Drivers
Table 2.2: Impact Analysis of Market Restraints
Table 4.1: Classification rules of IVDs under the IVDR
Table 4.2: Registration Criteria for IVD Medical Devices as per the CFDA
Table 6.1: Genetic Tests for Certain Applications
Table 6.2: Examples of Molecular Diagnostics in Cancer
Table 9.1: North America Molecular Diagnostics Market (by Application), 2017-2028
Table 9.2: Europe Molecular Diagnostics Market (by Application), 2017-2028
Table 9.4: APAC Molecular Diagnostics Market (by Application), 2017-2028
Table 9.6: Latin America Molecular Diagnostics Market (by Application), 2017-2028
Table 9.7: RoW Molecular Diagnostics Market (by Application), 2017-2028
Table 2.1: Impact Analysis of Market Drivers
Table 2.2: Impact Analysis of Market Restraints
Table 4.1: Classification rules of IVDs under the IVDR
Table 4.2: Registration Criteria for IVD Medical Devices as per the CFDA
Table 6.1: Genetic Tests for Certain Applications
Table 6.2: Examples of Molecular Diagnostics in Cancer
Table 9.1: North America Molecular Diagnostics Market (by Application), 2017-2028
Table 9.2: Europe Molecular Diagnostics Market (by Application), 2017-2028
Table 9.4: APAC Molecular Diagnostics Market (by Application), 2017-2028
Table 9.6: Latin America Molecular Diagnostics Market (by Application), 2017-2028
Table 9.7: RoW Molecular Diagnostics Market (by Application), 2017-2028
LIST OF FIGURES
Figure 1: Global Precision Medicine Market, 2016 and 2020
Figure 2: Impact of Market Drivers and Market Restraints on the Global Molecular Diagnostics Market
Figure 3: Global Molecular Diagnostics Market Snapshot
Figure 4: Dominating Segments of the Global Molecular Diagnostics Market, 2017 and 2028
Figure 5: Global Molecular Diagnostics Market (by Product), 2017 and 2028
Figure 6: Global Molecular Diagnostics Market (by Product), 2017
Figure 7: Global Molecular Diagnostics Market (by Product), 2028
Figure 8: Global Molecular Diagnostics Market (by Technology), 2017 and 2028
Figure 9: Global Molecular Diagnostics Market (by Technology), 2017 and 2028
Figure 10: Global Molecular Diagnostics Market (by Technology), 2017 and 2028
Figure 1.1: Role of Diagnostics in Healthcare
Figure 1.2: Evolution of Molecular Diagnostics
Figure 1.3: Classification of Molecular Diagnostics
Figure 1.4: Global Molecular Diagnostics (MDx) Market, 2017-2028
Figure 2.1: Iceberg Analysis - Global Molecular Diagnostics Market
Figure 2.2: Number of Deaths by Top 18 Infectious Diseases, 2015
Figure 2.3: Strategies to Integrate Personalized Medicine for Routine Healthcare Procedures
Figure 2.4: Benefits of Multiplexing Reactions
Figure 3.1: Share of Key Developments and Strategies, January 2016 - December 2018
Figure 3 2: Synergistic Activities Share (by Companies), January 2016 - December 2018
Figure 3.3: Approvals Share (by Companies), January 2016 – December 2018
Figure 3.4: Product Launches and Enhancements Share (by Companies), January 2016 – December 2018
Figure 3.5: Acquisitions Share (by Companies), January 2016 – December 2018
Figure 3.6: Market Share Analysis for the Global Molecular Diagnostics Market, 2016
Figure 3.7: Market Share Analysis for the Global Molecular Diagnostics Market, 2017
Figure 3.8: Growth Share Matrix (Opportunity Mapping Matrix) for Global Molecular Diagnostics Market (by companies), 2016
Figure 3.9: Growth Share Matrix (Opportunity Mapping Matrix) for Global Molecular Diagnostics Market (by companies), 2017
Figure 3.10: Overall Industry Attractiveness, 2018 and 2028
Figure 3.11: Overall Impact of Bargaining Power of Suppliers
Figure 3.12: Overall Impact of Bargaining Power of Buyers
Figure 3.13: Overall Impact of Threat of New Entrants
Figure 3.14: Overall Impact of Threat of Substitute Products
Figure 3.15: Overall Impact of Intensity of Competitive Rivalry
Figure 4.1: Components Considered for Clinical Evidence as per the IVDR
Figure 5.1: Global Molecular Diagnostics Market (by Product)
Figure 5.2: Global Molecular Diagnostics Market (by Product), 2017 and 2028
Figure 5.3: General Workflow of a Molecular Diagnostic Kit
Figure 5.4: Global Molecular Diagnostics Market (by Kits and Consumables), 2017-2028
Figure 5.5: Global Molecular Diagnostics Market (by Systems), 2017-2028
Figure 5.6: Global Molecular Diagnostics Market (by Systems, by Type), 2017-2028
Figure 5.7: Aspects of Software Development
Figure 5.8: Global Molecular Diagnostics Market (by Software and Other Products), 2017-2028
Figure 6.1: Global Molecular Diagnostics Market (by Application)
Figure 6.2: Global Molecular Diagnostics Market (by Application), 2017
Figure 6.3: Global Molecular Diagnostics Market (by Application), 2028
Figure 6.4: Global Molecular Diagnostics Market (by Core MDx Applications), 2017 and 2028
Figure 6.5: Nucleic Acid Testing Techniques for Infectious Diseases
Figure 6.6: Global Molecular Diagnostics Market (by Infectious Diseases), 2017-2028
Figure 6.7: Global Molecular Diagnostics Market (by Infectious Diseases), 2017 and 2028
Figure 6.8: Global Molecular Diagnostics Market (by Infectious Diseases, by Technology), 2017 and 2028
Figure 6.9: Global Molecular Diagnostics Market (by Genetic Testing), 2017-2028
Figure 6.10: Global Molecular Diagnostics Market (by Genetic Testing, by Technology), 2017 and 2028
Figure 6.11: Global Molecular Diagnostics Market (by Blood Donor Screening), 2017-2028
Figure 6.12: Clinical Uses of Molecular Diagnostics in Cancer
Figure 6.13: Global Molecular Diagnostics Market (by Cancer), 2017-2028
Figure 6.14: Global Molecular Diagnostics Market (by Oncology), 2017 and 2028
Figure 6.15: Global Molecular Diagnostics Market (by Oncology, by Technology), 2017 and 2028
Figure 6.16: Global Molecular Diagnostics Market (by HLA Testing), 2017-2028
Figure 6.17: Global Molecular Diagnostics Market (by Other Applications), 2017-2028
Figure 6.18: Global Molecular Diagnostics Market (by Companion Diagnostics), 2017 and 2028
Figure 6.19: Global Molecular Diagnostics Market (by NIPT, by Technology), 2017 and 2028
Figure 6.20: Global Molecular Diagnostics Market (by Companion Diagnostics), 2017 and 2028
Figure 6.21: Global Molecular Diagnostics Market (by Companion Diagnostics, by Technology), 2017 and 2028
Figure 6.22: Global Molecular Diagnostics Market (by Liquid Biopsy), 2017 and 2028
Figure 6.23: Global Molecular Diagnostics Market (by Liquid Biopsy, by Technology), 2017 and 2028
Figure 7.1: Global Molecular Diagnostics Market (by Technology)
Figure 7.2: Global Molecular Diagnostics Market (by Technology), 2017
Figure 7.3: Global Molecular Diagnostics Market (by PCR), 2017-2028
Figure 7.4: Evolution of Sequencing for Molecular Diagnostics
Figure 7.5: Global Molecular Diagnostics Market (by Sequencing), 2017-2028
Figure 7.6: Global Molecular Diagnostics Market (by Microarray), 2017-2028
Figure 7.7: Global Molecular Diagnostics Market (by ISH), 2017-2028
Figure 7.8: Global Molecular Diagnostics Market (by IHC), 2017-2028
Figure 7.9: Global Molecular Diagnostics Market (by NAA), 2017-2028
Figure 7.10: Global Molecular Diagnostics Market (by Isothermal Amplification), 2017-2028
Figure 7.11: Global Molecular Diagnostics Market (by Other Technologies), 2017-2028
Figure 8.1: Global Molecular Diagnostics Market (by End-User)
Figure 8.2: Global Molecular Diagnostics Market (by End-User), 2017 and 2028
Figure 8.3: Global Molecular Diagnostics Market (by Hospitals), 2017-2028
Figure 8.4: Global Molecular Diagnostics Market (by Diagnostic Centers), 2017-2028
Figure 8.5: Global Molecular Diagnostics Market (by Out-Patient Clinics/GPs), 2017-2028
Figure 8.6: Global Molecular Diagnostics Market (by Research Laboratories), 2017-2028
Figure 9.1: Global Molecular Diagnostics Market (by Region), 2017 and 2028
Figure 9.2: Global Molecular Diagnostics Market (by Region), 2017-2028
Figure 9.3: Global Molecular Diagnostics Market Share (by Region), 2017
Figure 9.4: Global Molecular Diagnostics Market Share (by Region), 2028
Figure 9.5: North America Molecular Diagnostics Market, 2017-2028
Figure 9.6: North America: Market Dynamics
Figure 9.7: North America Molecular Diagnostics Market (by Country), 2017-2028
Figure 9.8: The U.S. Molecular Diagnostics Market, 2017-2028
Figure 9.9: Canada Molecular Diagnostics Market, 2017-2028
Figure 9.10: Overview of Reimbursement Policies in Europe (Focus on Companion Diagnostics as well)
Figure 9.11: Europe Molecular Diagnostics Market, 2017-2028
Figure 9.12: Europe: Market Dynamics
Figure 9.13: Europe Molecular Diagnostics Market (by Country), 2017-2028
Figure 9.14: Germany Molecular Diagnostics Market, 2017-2028
Figure 9.15: France Molecular Diagnostics Market, 2017-2028
Figure 9.16: Italy Molecular Diagnostics Market, 2017-2028
Figure 9.17: The U.K. Molecular Diagnostics Market, 2017-2028
Figure 9 18: Spain Molecular Diagnostics Market, 2017-2028
Figure 9.19: The Netherlands Molecular Diagnostics Market, 2017-2028
Figure 9.20: Rest-of-Europe Molecular Diagnostics Market, 2017-2028
Figure 9.21: Asia-Pacific Molecular Diagnostics Market, 2017-2028
Figure 9.22: APAC: Market Dynamics
Figure 9.23: APAC Molecular Diagnostics Market (by Country), 2017-2028
Figure 9.24: Japan Molecular Diagnostics Market, 2017-2028
Figure 9.25: China Molecular Diagnostics Market, 2017-2028
Figure 9.26: India Molecular Diagnostics Market, 2017-2028
Figure 9.27: Australia Molecular Diagnostics Market, 2017-2028
Figure 9.28: Singapore Molecular Diagnostics Market, 2017-2028
Figure 9.29: RoAPAC Molecular Diagnostics Market, 2017-2028
Figure 9.30: Latin America Molecular Diagnostics Market, 2017-2028
Figure 9.31: Latin America: Market Dynamics
Figure 9.32: Latin America Molecular Diagnostics Market (by Country), 2017-2028
Figure 9.33: Brazil Molecular Diagnostics Market, 2017-2028
Figure 9.34: Mexico Molecular Diagnostics Market, 2017-2028
Figure 9.35: Rest-of-Latin America Molecular Diagnostics Market, 2017-2028
Figure 9.36: RoW Molecular Diagnostics Market, 2017-2028
Figure 10.1: Total Number of Companies Profiled
Figure 10.2: Abbott Laboratories: Overall Product Portfolio
Figure 10.3: Abbott Laboratories: Overall Financials, 2015-2017
Figure 10.4: Abbott Laboratories: Revenue (by Segment), 2015-2017
Figure 10.5: Abbott Laboratories: Revenue Split for Diagnostics, 2015-2017
Figure 10.6: Abbott Laboratories: Revenue (by Region), 2015-2017
Figure 10.7: Abbott Laboratories: R&D Expenditure, 2015-2017
Figure 10.8: Abbott Laboratories: Revenue Forecast, 2015-2020
Figure 10.9: Abbott Laboratories: SWOT Analysis
Figure 10.10: Agilent Technologies, Inc.: Overall Product Portfolio
Figure 10.11: Agilent Technologies, Inc.: Overall Financials, 2015-2017
Figure 10.12: Agilent Technologies, Inc.: Revenue (by Segment), 2015-2017
Figure 10.13: Agilent Technologies, Inc.: Revenue (by Region), 2015-2017
Figure 10.14: Agilent Technologies, Inc.: R&D Expenditure, 2015-2017
Figure 10.15: Agilent Technologies, Inc.: Revenue Forecast, 2015-2020
Figure 10.16: Agilent Technologies, Inc.: SWOT Analysis
Figure 10.17: Becton, Dickinson and Company: Overall Product Portfolio
Figure 10.18: Becton, Dickinson and Company: Overall Financials, 2015-2017
Figure 10.19: Becton, Dickinson and Company: Revenue (by Segment), 2015-2017
Figure 10.20: Becton, Dickinson and Company: Revenue Split for BD Life Sciences, 2015-2017
Figure 10.21: Becton, Dickinson and Company: Revenue (by Region), 2015-2017
Figure 10.22: Becton, Dickinson and Company: R&D Expenditure, 2015-2017
Figure 10.23: Becton, Dickinson and Company: Revenue Forecast, 2015-2020
Figure 10.24: Becton, Dickinson and Company: SWOT Analysis
Figure 10.25: bioMйrieux S.A.: Overall Product Portfolio
Figure 10.26: bioMйrieux S.A.: Overall Financials, 2015-2017
Figure 10.27: bioMйrieux S.A.: Revenue (by Segment), 2015-2017
Figure 10.28: bioMйrieux S.A.: Revenue (by Region), 2015-2017
Figure 10.29: bioMйrieux S.A.: R&D Expenditure, 2015-2017
Figure 10.30: bioMйrieux S.A.: Revenue Forecast, 2015-2020
Figure 10.31: bioMйrieux S.A.: SWOT Analysis
Figure 10.32: Bio-Rad Laboratories, Inc.: Overall Product Portfolio
Figure 10.33: Bio-Rad Laboratories, Inc.: Overall Financials, 2015-2017
Figure 10.34: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2015-2017
Figure 10.35: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2015-2017
Figure 10.36: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2015-2017
Figure 10.37: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 10.38: Cynvenio Biosystems, Inc.: Overall Product Portfolio
Figure 10.39: Cynvenio Biosystems, Inc.: SWOT Analysis
Figure 10.40: Danaher Corporation: Overall Product Portfolio
Figure 10.41: Danaher Corporation: Overall Financials, 2015-2017
Figure 10.42: Danaher Corporation: Revenue (by Segment), 2015-2017
Figure 10.43: Danaher Corporation: Revenue Split for Diagnostics, 2015-2017
Figure 10.44: Danaher Corporation: Revenue (by Region), 2015-2017
Figure 10.45: Danaher Corporation: R&D Expenditure, 2015-2017
Figure 10.46: Danaher Corporation: Revenue Forecast, 2015-2020
Figure 10.47: Danaher Corporation: SWOT Analysis
Figure 10.48: F. Hoffmann-La Roche AG: Overall Product Portfolio
Figure 10.49: F. Hoffmann-La Roche AG: Overall Financials, 2015-2017
Figure 10.50: F. Hoffmann-La Roche AG: Revenue (by Segment), 2015-2017
Figure 10.51: F. Hoffmann-La Roche AG: Revenue Split for Diagnostics, 2015-2017
Figure 10.52: F. Hoffmann-La Roche AG: Revenue (by Region), 2015-2017
Figure 10.53: F. Hoffmann-La Roche AG: R&D Expenditure, 2015-2017
Figure 10.54: F. Hoffmann-La Roche AG: Revenue Forecast, 2015-2020
Figure 10.55: F. Hoffmann-La Roche AG: SWOT Analysis
Figure 10.56: GUARDANT HEALTH, INC: Overall Product Portfolio
Figure 10.57: GUARDANT HEALTH, INC: SWOT Analysis
Figure 10.58: Illumina, Inc.: Overall Product Portfolio
Figure 10.59: Illumina, Inc.: Overall Financials, 2015-2017
Figure 10.60: Illumina, Inc.: Revenue (by Segment), 2015-2017
Figure 10.61: Illumina, Inc.: Revenue (by Region), 2015-2017
Figure 10.62: Illumina, Inc.: R&D Expenditure, 2015-2017
Figure 10.63: Illumina, Inc.: Revenue Forecast, 2015-2020
Figure 10.64: Illumina, Inc.: SWOT Analysis
Figure 10.65: Invivoscribe Technologies, Inc.: Overall Product Portfolio
Figure 10.66: Invivoscribe Technologies, Inc.: SWOT Analysis
Figure 10.67: MolecularMD Corporation: Overall Product Portfolio
Figure 10.68: MolecularMD Corporation: SWOT Analysis
Figure 10.69: QIAGEN N.V.: Overall Product Portfolio
Figure 10.70: QIAGEN N.V.: Overall Financials, 2015-2017
Figure 10.71: QIAGEN N.V.: Revenue (by Segment), 2015-2017
Figure 10.72: QIAGEN N.V.: Revenue (by Region), 2015-2017
Figure 10.73: QIAGEN N.V.: R&D Expenditure, 2015-2017
Figure 10.74: QIAGEN N.V.: Revenue Forecast, 2015-2020
Figure 10.75: QIAGEN N.V.: SWOT Analysis
Figure 10.76: Siemens Healthineers, Inc.: Overall Product Portfolio
Figure 10.77: Siemens Healthineers, Inc.: Overall Financials, 2016-2018
Figure 10.78: Siemens Healthineers, Inc.: Revenue (by Segment), 2016-2018
Figure 10.79: Siemens Healthineers, Inc.: Revenue (by Region), 2016-2018
Figure 10.80: Siemens Healthineers, Inc.: R&D Expenditure, 2016-2018
Figure 10.81: Siemens Healthineers, Inc.: Revenue Forecast, 2015-2020
Figure 10.82: Siemens Healthineers, Inc.: SWOT Analysis
Figure 10.83: Thermo Fisher Scientific Inc.: Overall Product Portfolio
Figure 10.84: Thermo Fisher Scientific Inc.: Overall Financials, 2015-2017
Figure 10.85: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2015-2017
Figure 10.86: Thermo Fisher Scientific Inc.: Revenue (by Region), 2015-2017
Figure 10.87: Thermo Fisher Scientific Inc.: R&D Expenditure, 2015-2017
Figure 10.88: Thermo Fisher Scientific Inc.: Revenue Forecast, 2015-2020
Figure 10.89: Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 10.90: QuantuMDx Group Ltd.: Overall Product Portfolio (Available from FY2019)
Figure 10.91: HTG Molecular Diagnostics, Inc.: Overall Product Portfolio
Figure 11.1: Global Molecular Diagnostics Market Segmentation
Figure 11.2: Global Molecular Diagnostics Market Research Methodology
Figure 11.3: Primary Research
Figure 11.4: Secondary Research
Figure 11.5: Data Triangulation
Figure 11.6: Bottom-up Approach (Segment-wise Analysis)
Figure 11.7: Top-down Approach (Segment-wise Analysis)
Figure 11.8: Assumptions and Limitations
Figure 11.9: Considered Factors for Data Prediction and Modeling
Figure 1: Global Precision Medicine Market, 2016 and 2020
Figure 2: Impact of Market Drivers and Market Restraints on the Global Molecular Diagnostics Market
Figure 3: Global Molecular Diagnostics Market Snapshot
Figure 4: Dominating Segments of the Global Molecular Diagnostics Market, 2017 and 2028
Figure 5: Global Molecular Diagnostics Market (by Product), 2017 and 2028
Figure 6: Global Molecular Diagnostics Market (by Product), 2017
Figure 7: Global Molecular Diagnostics Market (by Product), 2028
Figure 8: Global Molecular Diagnostics Market (by Technology), 2017 and 2028
Figure 9: Global Molecular Diagnostics Market (by Technology), 2017 and 2028
Figure 10: Global Molecular Diagnostics Market (by Technology), 2017 and 2028
Figure 1.1: Role of Diagnostics in Healthcare
Figure 1.2: Evolution of Molecular Diagnostics
Figure 1.3: Classification of Molecular Diagnostics
Figure 1.4: Global Molecular Diagnostics (MDx) Market, 2017-2028
Figure 2.1: Iceberg Analysis - Global Molecular Diagnostics Market
Figure 2.2: Number of Deaths by Top 18 Infectious Diseases, 2015
Figure 2.3: Strategies to Integrate Personalized Medicine for Routine Healthcare Procedures
Figure 2.4: Benefits of Multiplexing Reactions
Figure 3.1: Share of Key Developments and Strategies, January 2016 - December 2018
Figure 3 2: Synergistic Activities Share (by Companies), January 2016 - December 2018
Figure 3.3: Approvals Share (by Companies), January 2016 – December 2018
Figure 3.4: Product Launches and Enhancements Share (by Companies), January 2016 – December 2018
Figure 3.5: Acquisitions Share (by Companies), January 2016 – December 2018
Figure 3.6: Market Share Analysis for the Global Molecular Diagnostics Market, 2016
Figure 3.7: Market Share Analysis for the Global Molecular Diagnostics Market, 2017
Figure 3.8: Growth Share Matrix (Opportunity Mapping Matrix) for Global Molecular Diagnostics Market (by companies), 2016
Figure 3.9: Growth Share Matrix (Opportunity Mapping Matrix) for Global Molecular Diagnostics Market (by companies), 2017
Figure 3.10: Overall Industry Attractiveness, 2018 and 2028
Figure 3.11: Overall Impact of Bargaining Power of Suppliers
Figure 3.12: Overall Impact of Bargaining Power of Buyers
Figure 3.13: Overall Impact of Threat of New Entrants
Figure 3.14: Overall Impact of Threat of Substitute Products
Figure 3.15: Overall Impact of Intensity of Competitive Rivalry
Figure 4.1: Components Considered for Clinical Evidence as per the IVDR
Figure 5.1: Global Molecular Diagnostics Market (by Product)
Figure 5.2: Global Molecular Diagnostics Market (by Product), 2017 and 2028
Figure 5.3: General Workflow of a Molecular Diagnostic Kit
Figure 5.4: Global Molecular Diagnostics Market (by Kits and Consumables), 2017-2028
Figure 5.5: Global Molecular Diagnostics Market (by Systems), 2017-2028
Figure 5.6: Global Molecular Diagnostics Market (by Systems, by Type), 2017-2028
Figure 5.7: Aspects of Software Development
Figure 5.8: Global Molecular Diagnostics Market (by Software and Other Products), 2017-2028
Figure 6.1: Global Molecular Diagnostics Market (by Application)
Figure 6.2: Global Molecular Diagnostics Market (by Application), 2017
Figure 6.3: Global Molecular Diagnostics Market (by Application), 2028
Figure 6.4: Global Molecular Diagnostics Market (by Core MDx Applications), 2017 and 2028
Figure 6.5: Nucleic Acid Testing Techniques for Infectious Diseases
Figure 6.6: Global Molecular Diagnostics Market (by Infectious Diseases), 2017-2028
Figure 6.7: Global Molecular Diagnostics Market (by Infectious Diseases), 2017 and 2028
Figure 6.8: Global Molecular Diagnostics Market (by Infectious Diseases, by Technology), 2017 and 2028
Figure 6.9: Global Molecular Diagnostics Market (by Genetic Testing), 2017-2028
Figure 6.10: Global Molecular Diagnostics Market (by Genetic Testing, by Technology), 2017 and 2028
Figure 6.11: Global Molecular Diagnostics Market (by Blood Donor Screening), 2017-2028
Figure 6.12: Clinical Uses of Molecular Diagnostics in Cancer
Figure 6.13: Global Molecular Diagnostics Market (by Cancer), 2017-2028
Figure 6.14: Global Molecular Diagnostics Market (by Oncology), 2017 and 2028
Figure 6.15: Global Molecular Diagnostics Market (by Oncology, by Technology), 2017 and 2028
Figure 6.16: Global Molecular Diagnostics Market (by HLA Testing), 2017-2028
Figure 6.17: Global Molecular Diagnostics Market (by Other Applications), 2017-2028
Figure 6.18: Global Molecular Diagnostics Market (by Companion Diagnostics), 2017 and 2028
Figure 6.19: Global Molecular Diagnostics Market (by NIPT, by Technology), 2017 and 2028
Figure 6.20: Global Molecular Diagnostics Market (by Companion Diagnostics), 2017 and 2028
Figure 6.21: Global Molecular Diagnostics Market (by Companion Diagnostics, by Technology), 2017 and 2028
Figure 6.22: Global Molecular Diagnostics Market (by Liquid Biopsy), 2017 and 2028
Figure 6.23: Global Molecular Diagnostics Market (by Liquid Biopsy, by Technology), 2017 and 2028
Figure 7.1: Global Molecular Diagnostics Market (by Technology)
Figure 7.2: Global Molecular Diagnostics Market (by Technology), 2017
Figure 7.3: Global Molecular Diagnostics Market (by PCR), 2017-2028
Figure 7.4: Evolution of Sequencing for Molecular Diagnostics
Figure 7.5: Global Molecular Diagnostics Market (by Sequencing), 2017-2028
Figure 7.6: Global Molecular Diagnostics Market (by Microarray), 2017-2028
Figure 7.7: Global Molecular Diagnostics Market (by ISH), 2017-2028
Figure 7.8: Global Molecular Diagnostics Market (by IHC), 2017-2028
Figure 7.9: Global Molecular Diagnostics Market (by NAA), 2017-2028
Figure 7.10: Global Molecular Diagnostics Market (by Isothermal Amplification), 2017-2028
Figure 7.11: Global Molecular Diagnostics Market (by Other Technologies), 2017-2028
Figure 8.1: Global Molecular Diagnostics Market (by End-User)
Figure 8.2: Global Molecular Diagnostics Market (by End-User), 2017 and 2028
Figure 8.3: Global Molecular Diagnostics Market (by Hospitals), 2017-2028
Figure 8.4: Global Molecular Diagnostics Market (by Diagnostic Centers), 2017-2028
Figure 8.5: Global Molecular Diagnostics Market (by Out-Patient Clinics/GPs), 2017-2028
Figure 8.6: Global Molecular Diagnostics Market (by Research Laboratories), 2017-2028
Figure 9.1: Global Molecular Diagnostics Market (by Region), 2017 and 2028
Figure 9.2: Global Molecular Diagnostics Market (by Region), 2017-2028
Figure 9.3: Global Molecular Diagnostics Market Share (by Region), 2017
Figure 9.4: Global Molecular Diagnostics Market Share (by Region), 2028
Figure 9.5: North America Molecular Diagnostics Market, 2017-2028
Figure 9.6: North America: Market Dynamics
Figure 9.7: North America Molecular Diagnostics Market (by Country), 2017-2028
Figure 9.8: The U.S. Molecular Diagnostics Market, 2017-2028
Figure 9.9: Canada Molecular Diagnostics Market, 2017-2028
Figure 9.10: Overview of Reimbursement Policies in Europe (Focus on Companion Diagnostics as well)
Figure 9.11: Europe Molecular Diagnostics Market, 2017-2028
Figure 9.12: Europe: Market Dynamics
Figure 9.13: Europe Molecular Diagnostics Market (by Country), 2017-2028
Figure 9.14: Germany Molecular Diagnostics Market, 2017-2028
Figure 9.15: France Molecular Diagnostics Market, 2017-2028
Figure 9.16: Italy Molecular Diagnostics Market, 2017-2028
Figure 9.17: The U.K. Molecular Diagnostics Market, 2017-2028
Figure 9 18: Spain Molecular Diagnostics Market, 2017-2028
Figure 9.19: The Netherlands Molecular Diagnostics Market, 2017-2028
Figure 9.20: Rest-of-Europe Molecular Diagnostics Market, 2017-2028
Figure 9.21: Asia-Pacific Molecular Diagnostics Market, 2017-2028
Figure 9.22: APAC: Market Dynamics
Figure 9.23: APAC Molecular Diagnostics Market (by Country), 2017-2028
Figure 9.24: Japan Molecular Diagnostics Market, 2017-2028
Figure 9.25: China Molecular Diagnostics Market, 2017-2028
Figure 9.26: India Molecular Diagnostics Market, 2017-2028
Figure 9.27: Australia Molecular Diagnostics Market, 2017-2028
Figure 9.28: Singapore Molecular Diagnostics Market, 2017-2028
Figure 9.29: RoAPAC Molecular Diagnostics Market, 2017-2028
Figure 9.30: Latin America Molecular Diagnostics Market, 2017-2028
Figure 9.31: Latin America: Market Dynamics
Figure 9.32: Latin America Molecular Diagnostics Market (by Country), 2017-2028
Figure 9.33: Brazil Molecular Diagnostics Market, 2017-2028
Figure 9.34: Mexico Molecular Diagnostics Market, 2017-2028
Figure 9.35: Rest-of-Latin America Molecular Diagnostics Market, 2017-2028
Figure 9.36: RoW Molecular Diagnostics Market, 2017-2028
Figure 10.1: Total Number of Companies Profiled
Figure 10.2: Abbott Laboratories: Overall Product Portfolio
Figure 10.3: Abbott Laboratories: Overall Financials, 2015-2017
Figure 10.4: Abbott Laboratories: Revenue (by Segment), 2015-2017
Figure 10.5: Abbott Laboratories: Revenue Split for Diagnostics, 2015-2017
Figure 10.6: Abbott Laboratories: Revenue (by Region), 2015-2017
Figure 10.7: Abbott Laboratories: R&D Expenditure, 2015-2017
Figure 10.8: Abbott Laboratories: Revenue Forecast, 2015-2020
Figure 10.9: Abbott Laboratories: SWOT Analysis
Figure 10.10: Agilent Technologies, Inc.: Overall Product Portfolio
Figure 10.11: Agilent Technologies, Inc.: Overall Financials, 2015-2017
Figure 10.12: Agilent Technologies, Inc.: Revenue (by Segment), 2015-2017
Figure 10.13: Agilent Technologies, Inc.: Revenue (by Region), 2015-2017
Figure 10.14: Agilent Technologies, Inc.: R&D Expenditure, 2015-2017
Figure 10.15: Agilent Technologies, Inc.: Revenue Forecast, 2015-2020
Figure 10.16: Agilent Technologies, Inc.: SWOT Analysis
Figure 10.17: Becton, Dickinson and Company: Overall Product Portfolio
Figure 10.18: Becton, Dickinson and Company: Overall Financials, 2015-2017
Figure 10.19: Becton, Dickinson and Company: Revenue (by Segment), 2015-2017
Figure 10.20: Becton, Dickinson and Company: Revenue Split for BD Life Sciences, 2015-2017
Figure 10.21: Becton, Dickinson and Company: Revenue (by Region), 2015-2017
Figure 10.22: Becton, Dickinson and Company: R&D Expenditure, 2015-2017
Figure 10.23: Becton, Dickinson and Company: Revenue Forecast, 2015-2020
Figure 10.24: Becton, Dickinson and Company: SWOT Analysis
Figure 10.25: bioMйrieux S.A.: Overall Product Portfolio
Figure 10.26: bioMйrieux S.A.: Overall Financials, 2015-2017
Figure 10.27: bioMйrieux S.A.: Revenue (by Segment), 2015-2017
Figure 10.28: bioMйrieux S.A.: Revenue (by Region), 2015-2017
Figure 10.29: bioMйrieux S.A.: R&D Expenditure, 2015-2017
Figure 10.30: bioMйrieux S.A.: Revenue Forecast, 2015-2020
Figure 10.31: bioMйrieux S.A.: SWOT Analysis
Figure 10.32: Bio-Rad Laboratories, Inc.: Overall Product Portfolio
Figure 10.33: Bio-Rad Laboratories, Inc.: Overall Financials, 2015-2017
Figure 10.34: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2015-2017
Figure 10.35: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2015-2017
Figure 10.36: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2015-2017
Figure 10.37: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 10.38: Cynvenio Biosystems, Inc.: Overall Product Portfolio
Figure 10.39: Cynvenio Biosystems, Inc.: SWOT Analysis
Figure 10.40: Danaher Corporation: Overall Product Portfolio
Figure 10.41: Danaher Corporation: Overall Financials, 2015-2017
Figure 10.42: Danaher Corporation: Revenue (by Segment), 2015-2017
Figure 10.43: Danaher Corporation: Revenue Split for Diagnostics, 2015-2017
Figure 10.44: Danaher Corporation: Revenue (by Region), 2015-2017
Figure 10.45: Danaher Corporation: R&D Expenditure, 2015-2017
Figure 10.46: Danaher Corporation: Revenue Forecast, 2015-2020
Figure 10.47: Danaher Corporation: SWOT Analysis
Figure 10.48: F. Hoffmann-La Roche AG: Overall Product Portfolio
Figure 10.49: F. Hoffmann-La Roche AG: Overall Financials, 2015-2017
Figure 10.50: F. Hoffmann-La Roche AG: Revenue (by Segment), 2015-2017
Figure 10.51: F. Hoffmann-La Roche AG: Revenue Split for Diagnostics, 2015-2017
Figure 10.52: F. Hoffmann-La Roche AG: Revenue (by Region), 2015-2017
Figure 10.53: F. Hoffmann-La Roche AG: R&D Expenditure, 2015-2017
Figure 10.54: F. Hoffmann-La Roche AG: Revenue Forecast, 2015-2020
Figure 10.55: F. Hoffmann-La Roche AG: SWOT Analysis
Figure 10.56: GUARDANT HEALTH, INC: Overall Product Portfolio
Figure 10.57: GUARDANT HEALTH, INC: SWOT Analysis
Figure 10.58: Illumina, Inc.: Overall Product Portfolio
Figure 10.59: Illumina, Inc.: Overall Financials, 2015-2017
Figure 10.60: Illumina, Inc.: Revenue (by Segment), 2015-2017
Figure 10.61: Illumina, Inc.: Revenue (by Region), 2015-2017
Figure 10.62: Illumina, Inc.: R&D Expenditure, 2015-2017
Figure 10.63: Illumina, Inc.: Revenue Forecast, 2015-2020
Figure 10.64: Illumina, Inc.: SWOT Analysis
Figure 10.65: Invivoscribe Technologies, Inc.: Overall Product Portfolio
Figure 10.66: Invivoscribe Technologies, Inc.: SWOT Analysis
Figure 10.67: MolecularMD Corporation: Overall Product Portfolio
Figure 10.68: MolecularMD Corporation: SWOT Analysis
Figure 10.69: QIAGEN N.V.: Overall Product Portfolio
Figure 10.70: QIAGEN N.V.: Overall Financials, 2015-2017
Figure 10.71: QIAGEN N.V.: Revenue (by Segment), 2015-2017
Figure 10.72: QIAGEN N.V.: Revenue (by Region), 2015-2017
Figure 10.73: QIAGEN N.V.: R&D Expenditure, 2015-2017
Figure 10.74: QIAGEN N.V.: Revenue Forecast, 2015-2020
Figure 10.75: QIAGEN N.V.: SWOT Analysis
Figure 10.76: Siemens Healthineers, Inc.: Overall Product Portfolio
Figure 10.77: Siemens Healthineers, Inc.: Overall Financials, 2016-2018
Figure 10.78: Siemens Healthineers, Inc.: Revenue (by Segment), 2016-2018
Figure 10.79: Siemens Healthineers, Inc.: Revenue (by Region), 2016-2018
Figure 10.80: Siemens Healthineers, Inc.: R&D Expenditure, 2016-2018
Figure 10.81: Siemens Healthineers, Inc.: Revenue Forecast, 2015-2020
Figure 10.82: Siemens Healthineers, Inc.: SWOT Analysis
Figure 10.83: Thermo Fisher Scientific Inc.: Overall Product Portfolio
Figure 10.84: Thermo Fisher Scientific Inc.: Overall Financials, 2015-2017
Figure 10.85: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2015-2017
Figure 10.86: Thermo Fisher Scientific Inc.: Revenue (by Region), 2015-2017
Figure 10.87: Thermo Fisher Scientific Inc.: R&D Expenditure, 2015-2017
Figure 10.88: Thermo Fisher Scientific Inc.: Revenue Forecast, 2015-2020
Figure 10.89: Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 10.90: QuantuMDx Group Ltd.: Overall Product Portfolio (Available from FY2019)
Figure 10.91: HTG Molecular Diagnostics, Inc.: Overall Product Portfolio
Figure 11.1: Global Molecular Diagnostics Market Segmentation
Figure 11.2: Global Molecular Diagnostics Market Research Methodology
Figure 11.3: Primary Research
Figure 11.4: Secondary Research
Figure 11.5: Data Triangulation
Figure 11.6: Bottom-up Approach (Segment-wise Analysis)
Figure 11.7: Top-down Approach (Segment-wise Analysis)
Figure 11.8: Assumptions and Limitations
Figure 11.9: Considered Factors for Data Prediction and Modeling
